Key Words: angiotensin II-induced hypertension Ⅲ renin-angiotensin system Ⅲ high-performance liquid chromatography Ⅲ intrarenal angiotensin II Ⅲ urinary angiotensin II P revious studies have demonstrated that intrarenal angiotensin (Ang) II content is significantly elevated in chronic Ang II-infused rats. 1-3 The increases in circulating Ang II lead to progressive augmentation of intrarenal Ang II. The plasma renin activity (PRA) is markedly reduced in the Ang II-infused rats, 1,2,4 -6 whereas the kidney renin content and renin mRNA are not reduced to the same extent, which indicates that the sustained intrarenal renin activity may contribute to the augmented or sustained intrarenal Ang II levels. 1,7-9 Because Ang II type 1 (AT 1 ) receptor blockers markedly diminish the increase in intrarenal Ang II content in Ang II-infused rats, the augmentation of intrarenal Ang II is partially attributed to AT 1 receptor-mediated binding and internalization of circulating Ang II. 2, 3, 7, 10, 11 In addition, renal angiotensinogen (AGT) activity, AGT mRNA, protein, and renal Ang I contents, as well as intrarenal angiotensinconverting enzyme activity, are either increased or not reduced from the control levels, suggesting that there is also enhanced de novo formation of Ang II in the kidney. 2, 7, [12] [13] [14] [15] Our recent study demonstrated that rats infused chronically with Val 5 -Ang II exhibit increased urinary excretion of endogenous Ile 5 -Ang II by the 12th day of infusion, indicating the stimulation of endogenous Ang II formation. 16 Several other studies have reported that the augmentation of intrarenal AGT in chronic Ang II infusion depends on activation of AT 1 receptors. Chronic Ang II infusion leads to increases in urinary excretion of AGT, and enhanced urinary excretion rates of AGT are the consequence of the stimulation of AGT production by the kidney. 7, 12, 17, 18 These results provide further evidence that there is an enhanced intrarenal endogenous production of Ang II with subsequent augmentation of endogenous Ang II excretion in the urine in Val 5 -Ang II-infused rats. However, the relative quantitative contribution of enhanced endogenous Ang II production versus accumulation of circulating Ang II has not been established.
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-Ang II infusion. The present study determined the time course of increased urinary Ang II excretion and the effects of Ang II type 1 receptor blockade (candesartan, 2 mg/kg per day) on the urinary excretion rates of Ile 5 Key Words: angiotensin II-induced hypertension Ⅲ renin-angiotensin system Ⅲ high-performance liquid chromatography Ⅲ intrarenal angiotensin II Ⅲ urinary angiotensin II P revious studies have demonstrated that intrarenal angiotensin (Ang) II content is significantly elevated in chronic Ang II-infused rats. [1] [2] [3] The increases in circulating Ang II lead to progressive augmentation of intrarenal Ang II. The plasma renin activity (PRA) is markedly reduced in the Ang II-infused rats, 1,2,4 -6 whereas the kidney renin content and renin mRNA are not reduced to the same extent, which indicates that the sustained intrarenal renin activity may contribute to the augmented or sustained intrarenal Ang II levels. 1, [7] [8] [9] Because Ang II type 1 (AT 1 ) receptor blockers markedly diminish the increase in intrarenal Ang II content in Ang II-infused rats, the augmentation of intrarenal Ang II is partially attributed to AT 1 receptor-mediated binding and internalization of circulating Ang II. 2, 3, 7, 10, 11 In addition, renal angiotensinogen (AGT) activity, AGT mRNA, protein, and renal Ang I contents, as well as intrarenal angiotensinconverting enzyme activity, are either increased or not reduced from the control levels, suggesting that there is also enhanced de novo formation of Ang II in the kidney. 2, 7, [12] [13] [14] [15] Our recent study demonstrated that rats infused chronically with Val 5 -Ang II exhibit increased urinary excretion of endogenous Ile 5 -Ang II by the 12th day of infusion, indicating the stimulation of endogenous Ang II formation. 16 Several other studies have reported that the augmentation of intrarenal AGT in chronic Ang II infusion depends on activation of AT 1 receptors. Chronic Ang II infusion leads to increases in urinary excretion of AGT, and enhanced urinary excretion rates of AGT are the consequence of the stimulation of AGT production by the kidney. 7, 12, 17, 18 These results provide further evidence that there is an enhanced intrarenal endogenous production of Ang II with subsequent augmentation of endogenous Ang II excretion in the urine in Val 5 -Ang II-infused rats. However, the relative quantitative contribution of enhanced endogenous Ang II production versus accumulation of circulating Ang II has not been established. Also, it has not been determined whether the increased endogenous Ang II in the urine is attributed to increased filtered Ang II or increased intratubular formation and/or secretion. Finally, the specific role of AT 1 receptors in mediating the increased intrarenal and urinary endogenous Ang II has not been established. The objective of this study was to determine the time course of increased endogenous urinary Ang II excretion and the effects of AT 1 
Materials and Methods

Animal Preparation
Male Sprague-Dawley rats weighing 330 to 350 g (Charles River Laboratories) were housed in wire cages under controlled temperature and lighting conditions. Throughout the experiments, the animals had free access to tap water and standard rat chow (Ralston Purina). All of the experiments were approved by the Tulane University Animal Care and Use Committee. Rats were divided into 2 experimental groups: rats infused with Val 5 -Ang II (nϭ5) and rats infused with Val 5 -Ang II and treated with AT 1 receptor antagonist, candesartan (nϭ6). Candesartan (AstraZeneca) was administered in the drinking water at a dose of 2 mg/kg per day to allow chronic treatment throughout the period of Ang II infusion. Ang II was delivered continuously at a rate of 80 ng/min via osmotic minipump (model 2002, Durect Corp) that was implanted subcutaneously at the dorsum of the neck. Systolic blood pressure (SBP) was measured in conscious rats by tail-cuff plethysmography (Visitech Systems, Inc) to monitor the progression of hypertension. 16 The rats were decapitated on day 13, and trunk blood was collected and the kidneys were immediately removed, quickly weighed, and homogenized in methanol. The time delay between decapitation and homogenization of the kidneys did not exceed 60 seconds.
Collection and Extraction of Blood, Kidney, and Urine Samples
Blood was collected in chilled tubes containing a mixed inhibitor solution (final concentration: 5 mmol/L of EDTA, 20 mol/L of pepstatin, 10 mol/L of PMSF, 20 mol/L of enalaprilat, and 1.25 mmol/L of 1,10-phenanthroline). After centrifugation at 4°C for 10 minutes at 1000g, plasma was separated and applied to phenylbonded solid-phase extraction columns (Bond-Elut, Varian) that had been prewashed with 90% methanol followed by water. After sample application, each solid-phase extraction column was washed sequentially with water, hexane, and chloroform. Angiotensin peptides were eluted from the solid-phase extraction column with 90% methanol. 19 The eluants were collected, evaporated to dryness under vacuum, and then subjected to HPLC to separate Val 5 -Ang II from Ile 5 -Ang II. 3, 19 For tissue Ang II measurements, each kidney was immersed in cold methanol (100%), minced, and homogenized with polytron tissue tearor immediately after harvesting and weighing. The homogenates were centrifuged, and the supernatants from the kidney homogenates were dried overnight in a vacuum centrifuge. The dried residue was reconstituted in 1 mL of radioimmunoassay buffer (19 mmol/L of monobasic sodium phosphate, 81 mmol/L of dibasic sodium phosphate, 0.05 mol/L of sodium chloride, 0.1% BSA, 0.1% Triton x-100, and 0.01% sodium azide [pH 7.4]). These samples were extracted and evaporated as described above for plasma and subjected to HPLC. Urine was collected in tubes containing the same mixed inhibitor solution as for blood. Collection was carried out for 24 hours on the day before Ang II infusion was started and on days 3, 6, 9, and 12 during the chronic Ang II infusions. Urine was centrifuged, and representative 1.0 mL aliquots of the supernatants were extracted and evaporated as described above for plasma and subjected to HPLC.
Separation of Val
-Ang II From Ile
-Ang II by HPLC
The HPLC and radioimmunoassay methodologies for the measurement of Ang peptides were similar to those described previously, with some modification. 3,11,19 -21 Briefly, the dried extract residue from each sample was resuspended with a 250-L equilibration solvent, which included 65% mobile phase A (0.13% heptafluorobutyric acid) and 35% mobile phase B (80.00% acetonitrile/0.13% heptafluorobutyric acid). A 200-L aliquot of supernatant was chromatographed by isocratic elution at 1 mL/min on a 25.00ϫ0.46-cm, 5-m Vydac C18 reverse-phase HPLC column (Separations Group). Val 5 -Ang II eluted at 9 minutes, and Ile 5 -Ang II had an elution peak at 12 minutes. Fractions were collected from 8 to 10 minutes for Val 5 -Ang II and from 11 to 13 minutes for Ile 5 -Ang II, evaporated to dryness, reconstituted in assay diluent, and measured directly by radioimmunoassay. For the present study, particular care was given to the prevention of any carryover of the peptides from the calibration procedures to the experimental samples.
Measurement of Val
-Ang II and Ile
-Ang II by Radioimmunoassay
The reconstituted fractions were incubated with rabbit anti-Ang II antisera (Peninsula Laboratories Inc) and 125 I-radiolabeled Ang II (Perkin Elmer Life and Analytic Sciences) for 48 hours at 4°C. Bound and free Ang peptides were separated by dextran-coated charcoal, and the supernatants were counted on a computer-linked gamma counter for 3 minutes. Immunoreactivities of the antibody for Val 5 -Ang II and Ile 5 -Ang II were virtually identical. The sensitivity of the Ang II assay was 0.97 fmol. For the Ang II assays, the specific binding was 76.8%, and nonspecific binding was 6.2%.
PRA and Kidney Prorenin and Renin Content Assays
For PRA determinations, trunk blood was collected in chilled tubes containing EDTA (5 mmol/L). Plasma was separated and stored at Ϫ20°C until assayed with a commercially available GammaCoat Plasma Renin Activity 125 I-Ang I Radioimmunoassay kit (DiaSorin Inc). 1, 16 For kidney prorenin and renin content assessment, each kidney was immersed in cold kidney renin content homogenation buffer (2.6 mmol/L of EDTA, 3.4 mmol/L of hydroxyquinoline, 5.0 mmol/L of ammonium acetate, 200.0 mol/L of PMSF, and 0.3 mol/L of dimercaprol), minced, and homogenized. 16 The homogenates were centrifuged and the supernatants were used to generate 1:1000 dilutions. Ten microliters of diluted kidney extract were incubated with trypsin (0.25 mg/mL) in the presence of BSA (10 mg/mL) and CaCl 2 (5mmol/L) for 1 hour at 4°C. The reaction was stopped by adding soybean trypsin inhibitor (0.5 mg/mL) for 10 minutes at room temperature. The diluted kidney extracts treated with trypsin and without trypsin were spiked with 1 mol/L of synthetic renin tetradecapeptide substrate, and the generated Ang I was assayed with the Diasorin PRA radioimmunoassay kit for the prorenin and renin measurements. 22, 23 
Statistical Analysis
Results are expressed as meanϮSE. For Figures 1 and 6 , the data were analyzed by repeated-measures ANOVA with post hoc Newman-Keuls multiple comparison test within each group, and the data were analyzed by 1-way ANOVA with post hoc Newman-Keuls multiple comparison test between 2 groups. We used student unpaired t test to analyze the data for Figures 2, 4 , and 5. When compared with the third group from the previous publication in Figure 2 , we applied a 1-way ANOVA. A value of PϽ0.05 was considered statistically significant.
Results
Effect of Candesartan on SBP During Val
-Ang II Infusion
SBP increased significantly from 113Ϯ1 to 215Ϯ2 mm Hg in the Val 5 -Ang II-infused rats. In the candesartan-treated rats, SBP was slightly lower initially and remained in the normotensive range throughout the duration of the experiment (107Ϯ3 to 124Ϯ3 mm Hg; Figure 1 ). Figure 4 ). There were no differences in the plasma Ile 5 -Ang II levels between the sham-operated rats (44.1Ϯ1.5 fmol/mL) and Figure 6 ).
Effect of
Effect of Candesartan on
Discussion
Previous studies have shown that intrarenal Ang II levels are augmented during Ang II-induced hypertension 1-3,13 because of AT 1 receptor-mediated uptake of circulating Ang II, as well as increased formation of endogenous Ang II. 2, 3, 11 In our recent study, 16 we confirmed that there was an elevated Val 5 -Ang II in the kidneys of Val 5 -Ang II-infused rats. We further reported that there was a significant augmentation of endogenous Ile 5 -Ang II levels in the kidneys that was greater than could be explained from equilibration with the circulating Ile 5 -Ang II concentration, thus demonstrating increased de novo formation of endogenous Ile 5 -Ang II. 16 The present study addressed the important question regarding the role of the AT 1 receptor in mediating the augmentation of endogenous Ang II.
In the Val 5 -Ang II-infused rats, the SBP begin to increase by day 3 and progressively increased over the course of the 2 weeks; candesartan treatment for rats infused with Val 5 -Ang II for 13 days prevented the progressive increase in SBP. The PRA levels were markedly suppressed in the Val 5 -Ang II-infused rats but not in the candesartan-treated rats, thereby indicating the importance of AT 1 receptor activation in the Ang II-induced negative feedback effect on renin release. 1, 6, [25] [26] [27] [28] Interestingly, the kidney prorenin and renin contents were not suppressed in Val 5 -Ang II-infused rats. These results are consistent with previous reports that the kidney renin mRNA, renin protein, and kidney renin content are not suppressed to the same extent as PRA. 1, 8, 26, 27 Indeed, renin expression in collecting duct cells of the distal nephron actually increases in Ang II-infused rats. 8, 9 Thus, the KRC was not suppressed in the Val 5 -Ang II-infused rats, which would allow the possibility of increased endogenous intrarenal Ang II formation. In the Val 5 -Ang II-infused rats treated 
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Renin-Angiotensin System 381 with candesartan, the plasma endogenous Ile 5 -Ang II levels were elevated, which can be explained by the increased circulating renin activity. 2, 11 13 showed that Ang II levels in renal cortical endosomes and intermicrovillar clefts are markedly increased in Ang II-infused hypertensive rats, and concurrent administration of candesartan prevented the increase in endosomes and intermicrovillar cleft Ang II levels. This study demonstrated that there is increased AT 1 receptor-mediated intracellular trafficking/accumulation of circulating and/or intrarenal-formed Ang II into cortical tubular endosomes during Ang II-dependent hypertension, which is blocked by an Ang receptor blocker. The internalized Ang II or Ang II-AT 1 receptor complex may migrate to the nucleus to exert genomic effects, 29 -31 because there are nuclear binding sites for Ang II in renal cells. 32 In addition, chronic Ang II infusions increased intrarenal AGT mRNA levels causing enhanced intrarenal production of AGT, suggesting additional de novo Ang II generation, which contributes further to the increased intrarenal Ang II levels. 7, 12, 14, 28, 33 In addition, AGT and Ang II are present in very high concentrations in proximal tubular fluid. 17, 18, 34, 35 In our current study, candesartan had a more profound effect on Ile 5 -Ang II production than uptake of Val 5 -Ang II into renal tissue, which provides quantitative evidence supporting the idea that there is a positive amplification mechanism resulting in the increases in de novo intrarenal endogenous Ang II formation in Ang II-induced hypertension.
The present study demonstrates that the urinary Ile 5 -Ang II excretion rates by day 12 were significantly greater than those measured in the same rats on the day before the start of Val 5 -Ang II infusion. Furthermore, the urinary Ile 5 -Ang II excretion rates increased progressively and were significantly elevated by day 9 in the Val 5 -Ang II-infused rats and significantly greater than in the candesartan-treated rats. In candesartan-treated rats, the Ile 5 -Ang II excretion rate was reduced by 82%, and Val 5 -Ang II excretion rate was reduced by 30%. These percentage reductions are similar to the reductions of intrarenal Ang II content, being 94% for Ile 5 -Ang II and 37% for Val 5 -Ang II. These results indicate that the increased urinary Ang II excretion rate is positively related to the elevation of intrarenal Ang II during Ang IIinduced hypertension and that changes in the urinary Ang II excretion rates are a reflection of changes in intrarenal Ang II levels. Zou et al 2 reported that, in Ang II-infused rats, plasma Ang II levels were elevated by day 3 of Ang II infusion; however, the intrarenal Ang II, measured at days 3, 7, 10, and 13, increased slightly by day 7 and were significantly elevated by day 10. The differences in the time-related changes in circulating and intrarenal Ang II levels suggested a slowly developing effect of circulating Ang II to enhance intrarenal Ang II. The time pattern of the augmentation of intrarenal Ang II observed by Zou et al 2 is closely matched by the enhanced urinary Ile 5 -Ang II excretion rates that we observed. Also, urinary excretion rates of AGT in Ang IIinfused rats become significantly increased at day 8 compared with sham rats, 33 and basal renal plasma flow and glomerular filtration rate levels in chronic Ang II-infused rats and those treated with a Ang receptor blocker are similar. 36 These results support the hypothesis that the augmented urinary endogenous Ang II originates from the kidney and not from the filtration of circulating endogenous Ang II, which was actually decreased in the Val 5 -Ang II-infused rats. Administration of Ang II increases mRNA expression of renal and hepatic AGT production 28 and directly increases AGT production and AGT mRNA levels in cultured proximal tubular cells, 37 supporting the hypothesis that intrarenal AGT protein is predominately localized to proximal tubular cells. 14, [37] [38] [39] [40] [41] [42] [43] [44] Furthermore, the increased AGT in the urine in Ang II-dependent hypertension indicates that AGT traverses the entire nephron segments. 7 Komlosi et al 45 reported that Ang II was formed intraluminally in the collecting duct in the presence of angiotensin-converting enzyme. Furthermore, the increases in renal AGT and urinary AGT excretion rate are mediated by AT 1 receptor activation 7 and lead to increased AGT secretion into the tubular lumen, which would lead to increased spillover of AGT into distal nephron segments, where it could then be acted on by renin and angiotensinconverting enzyme in collecting duct cells, leading to enhanced urinary excretion rates of Ang II. 9 Accordingly, the present data support the hypothesis that the increased urinary endogenous Ile 5 -Ang II excretion in Val 5 -Ang II-infused rats is not derived from the circulating Ile 5 -Ang II but is attributed to enhanced secretion into and/or de novo formation of intrarenal endogenous Ile 5 -Ang II mediated by AT 1 receptors.
Perspectives
This study demonstrates that chronic Ang II infusions to normal rats significantly increase urinary excretion of endogenous Ile 5 -Ang II in a time-dependent manner that was associated with elevated intrarenal endogenous Ile 5 -Ang II levels, and they are both mediated by AT 1 receptors. The urinary excretion of endogenous Ang II may be an indicator of increased distal nephron Ang II production in Ang IIdependent hypertension, which could augment distal sodium reabsorption. It is possible that, in human subjects, the measurement of urinary excretion of Ang II can be used as one of the biomarkers in hypertensive patients to monitor the efficacy of drugs that block the actions of the renin-angiotensin system and, thus, contribute to an optimized treatment.
